Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients (Preedom)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00768196
First received: October 1, 2008
Last updated: December 6, 2010
Last verified: December 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to asses the EED symptom prevalence in Koran GERD patients with typical reflux symptom and to evaluate quality of life with the scales including Gerd Q.
| Condition |
|---|
|
Gastroesophageal Reflux Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- The primary variable is the total rate of GERD patients who had EED symptom and effect on their quality of life.
Secondary Outcome Measures:
- The secondary variable is the comparison of the EED symptom frequency in ERD and NERD patients.
| Estimated Enrollment: | 2000 |
| Study Start Date: | September 2008 |
| Study Completion Date: | February 2009 |
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
general hospital sample
Criteria
Inclusion Criteria:
- GERD patients who have experienced heartburn or acid regurgitation during past 7 days
- GERD patients who have already undergone endoscopy before enrolment
Exclusion Criteria:
- Involvement in the planning and conduct of the programme
- The person who took the medicine such as PPI or H2RA during the last 7 days
- Severe systemic disease
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00768196
Locations
| Korea, Republic of | |
| Research Site | |
| Cheonan, Chungnam, Korea, Republic of | |
| Research Site | |
| Seoul, Kyungkido, Korea, Republic of | |
| Research Site | |
| Sungnam, Kyungkido, Korea, Republic of | |
| Research Site | |
| Suwon, Kyungkido, Korea, Republic of | |
Sponsors and Collaborators
AstraZeneca
Investigators
| Study Director: | Joon-Woo Bahn | AstraZeneca Korea |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00768196 History of Changes |
| Other Study ID Numbers: | NIS-GKR-DUM-2008/1 |
| Study First Received: | October 1, 2008 |
| Last Updated: | December 6, 2010 |
| Health Authority: | Korea: Food and Drug Administration |
Keywords provided by AstraZeneca:
|
GERD Korea typical symptom |
quality of life Naturalistic epidemiological |
Additional relevant MeSH terms:
|
Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders |
Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013